Tinsley S, Stephens A, Morrison C, Richard C, Hares K, Lutchka J
J Racial Ethn Health Disparities. 2025; .
PMID: 40048083
DOI: 10.1007/s40615-025-02350-8.
Desmond C, Kaul S, Fleishman A, Korets R, Chang P, Wagner A
Prostate Cancer Prostatic Dis. 2024; .
PMID: 38555410
DOI: 10.1038/s41391-024-00822-2.
Hu S, Chang C, Snyder J, Deshmukh V, Newman M, Date A
JCO Clin Cancer Inform. 2023; 7:e2300083.
PMID: 37988640
PMC: 10681553.
DOI: 10.1200/CCI.23.00083.
Moll M, DAndrea D, Zaharie A, Grubmuller B, Paschen C, Zehetmayer S
Strahlenther Onkol. 2022; 198(8):719-726.
PMID: 35284951
PMC: 9300528.
DOI: 10.1007/s00066-022-01909-2.
Staby Olsen J, Estefan D, Valachis A, Jakobsson F, Karlsson L, Johansson B
J Contemp Brachytherapy. 2022; 14(1):7-14.
PMID: 35233229
PMC: 8867235.
DOI: 10.5114/jcb.2022.113545.
Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial.
Jones C, Pugh S, Sandler H, Chetner M, Amin M, Bruner D
Int J Radiat Oncol Biol Phys. 2021; 112(2):294-303.
PMID: 34481017
PMC: 8748315.
DOI: 10.1016/j.ijrobp.2021.08.031.
Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer.
Moll M, Renner A, Kirisits C, Paschen C, Zaharie A, Goldner G
Strahlenther Onkol. 2021; 197(11):986-992.
PMID: 34351453
PMC: 8547207.
DOI: 10.1007/s00066-021-01815-z.
Race and prostate specific antigen surveillance testing and monitoring 5-years after definitive therapy for localized prostate cancer.
Asiri I, Chen R, Young H, Codling J, Mandawat A, Beach S
Prostate Cancer Prostatic Dis. 2021; 24(4):1093-1102.
PMID: 33941865
PMC: 8563495.
DOI: 10.1038/s41391-021-00365-w.
A novel immune-related gene-based prognostic signature to predict biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Lv D, Wu X, Chen X, Yang S, Chen W, Wang M
Cancer Immunol Immunother. 2021; 70(12):3587-3602.
PMID: 33934205
PMC: 10992206.
DOI: 10.1007/s00262-021-02923-6.
Interim and end-treatment F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride.
Garcia Vicente A, Amo-Salas M, Espinosa J, Gomez Diaz R, Soriano Castrejon A
Sci Rep. 2021; 11(1):7389.
PMID: 33795764
PMC: 8016973.
DOI: 10.1038/s41598-021-86759-1.
A new risk stratification system of prostate cancer to identify high-risk biochemical recurrence patients.
Wu X, Lv D, Eftekhar M, Khan A, Cai C, Zhao Z
Transl Androl Urol. 2021; 9(6):2572-2586.
PMID: 33457230
PMC: 7807327.
DOI: 10.21037/tau-20-1019.
Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer.
Liu Y, Hall I, Filson C, Howard D
Urol Oncol. 2020; 39(7):432.e1-432.e10.
PMID: 33308973
PMC: 8374746.
DOI: 10.1016/j.urolonc.2020.11.024.
Circular RNAs and Their Linear Transcripts as Diagnostic and Prognostic Tissue Biomarkers in Prostate Cancer after Prostatectomy in Combination with Clinicopathological Factors.
Rochow H, Jung M, Weickmann S, Ralla B, Stephan C, Elezkurtaj S
Int J Mol Sci. 2020; 21(21).
PMID: 33105568
PMC: 7672590.
DOI: 10.3390/ijms21217812.
Effect of upregulation of DD3 on early detection and prognosis in prostate cancer.
Wang K, Zhao H, Wang W, Zhu Y, Zhang X, Ma J
Transl Androl Urol. 2020; 9(4):1550-1558.
PMID: 32944517
PMC: 7475679.
DOI: 10.21037/tau-19-899.
Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications.
Brandao A, Paulo P, Teixeira M
Int J Mol Sci. 2020; 21(14).
PMID: 32708810
PMC: 7404100.
DOI: 10.3390/ijms21145036.
Understanding primary care-oncology relationships within a changing healthcare environment.
Tsui J, Howard J, OMalley D, Miller W, Hudson S, Rubinstein E
BMC Fam Pract. 2019; 20(1):164.
PMID: 31775653
PMC: 6882058.
DOI: 10.1186/s12875-019-1056-y.
A Novel Predictor Tool of Biochemical Recurrence after Radical Prostatectomy Based on a Five-MicroRNA Tissue Signature.
Zhao Z, Weickmann S, Jung M, Lein M, Kilic E, Stephan C
Cancers (Basel). 2019; 11(10).
PMID: 31640261
PMC: 6826532.
DOI: 10.3390/cancers11101603.
Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study.
Asamoah F, Yarney J, Awasthi S, Vanderpuye V, Dadzie M, Fink A
Am J Clin Oncol. 2019; 42(12):937-944.
PMID: 31584456
PMC: 6887629.
DOI: 10.1097/COC.0000000000000589.
Prediction of Recurrence-associated Death from Localized Prostate Cancer with a Charlson Comorbidity Index-reinforced Machine Learning Model.
Lin Y, Lee M, Huang Y, Liu C, Li Y, Chen M
Open Med (Wars). 2019; 14:593-606.
PMID: 31428684
PMC: 6698054.
DOI: 10.1515/med-2019-0067.
An electronic registry to improve adherence to active surveillance monitoring among men with prostate cancer at a safety-net hospital: protocol for a pilot study.
Cedars B, Lisker S, Borno H, Kamal P, Breyer B, Sarkar U
Pilot Feasibility Stud. 2019; 5:101.
PMID: 31428442
PMC: 6694525.
DOI: 10.1186/s40814-019-0482-x.
